01/22/2024
Amidst the darkest times of the COVID-19 global pandemic and dire limitations on physical contacts/presence, Novartis Pharmaceuticals sought to relaunch Xiidra, a first-in-class treatment for dry eyes, in the United States. Due to obvious reasons, it could only leverage a digital-only strategy to drive sales.
The question was, "How to ensure the desired success and sales within a situation like this?" Well, that's where Novartis crossed paths with The Keshri Group.
The goal was to increase brand awareness, educate healthcare professionals about Xiidra's benefits, and navigate them to the prospects.
We collaborated closely with Novartis to ensure alignment with the company's marketing objectives. Accordingly, we came up with the strategy. We leveraged analytics and campaign performance evaluation for a data-driven approach.
Accordingly, we assisted Novartis with our , , , , and Services.
The result was resounding! Xiidra was launched successfully within a challenging environment, demonstrating the effectiveness of a data-driven, digital-first approach to pharmaceutical marketing. Going beyond their expectations, Keshri was able to help Novartis Pharma make a 35-million-dollar sale in its first month! We were also able to generate:
-20% Increase in Website Traffic
-30% Increase in Brand Awareness Among Healthcare Professionals (HCPs)
-15% Increase in Prescriptions
